Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human platelets Clear all
Completed Phase 2 Interventional

Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing

NCT06632418
View directory record Official record
Conditions
Anal Fistula, Complex Perianal Fistula
Interventions
RhPDGF-BB
Drug
Lead sponsor
Alexander Hawkins
Other
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 13, 2026, 2:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ultrasound of the Spleen Utilizing Low-energy (Diagnostic Level) Insonification.

NCT06934096
View directory record Official record
Conditions
Hemostasis, Blood Biomarkers, Ultrasound
Interventions
Ultrasound Pulsed Doppler Imaging System
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT02640807
View directory record Official record
Conditions
Severe Sepsis With Septic Shock
Interventions
Interleukin-7, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

NCT00368238
View directory record Official record
Conditions
Healthy Subjects
Interventions
Recombinant human erythropoietin alfa (drug), Aspirin (drug), Clopidogrel (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2006 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

NCT04822363
View directory record Official record
Conditions
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 13, 2026, 2:49 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

NCT05284032
View directory record Official record
Conditions
Platelet Refractoriness, Hematologic Malignancy
Interventions
isatuximab 10 mg/kg
Drug
Lead sponsor
Firas El Chaer, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 13, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional Results available

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

NCT01283321
View directory record Official record
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 13, 2026, 2:49 AM EDT
Completed No phase listed Observational

Pilot Study of Mitochondrial Biology in Human Platelets

NCT00833846
View directory record Official record
Conditions
Insulin Resistance, Diabetes
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 13, 2026, 2:49 AM EDT
Active, not recruiting Phase 4 Interventional

Connective Tissue Matrix for Rotator Cuff Tendinopathy

NCT06160427
View directory record Official record
Conditions
Tendinopathy, Shoulder Pain, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis
Interventions
CTM Boost, PRP
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis

NCT03289416
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Pure PRP II, PureBMC
Combination Product
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 13, 2026, 2:49 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Rh-PDGF vs EMD for Treatment of Intra-bony Defects

NCT05442034
View directory record Official record
Conditions
Intrabony Periodontal Defect
Interventions
growth factors to help in regeneration
Biological
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 2Phase 3 Interventional

DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)

NCT04709705
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Human platelets
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

NCT01134055
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, placebo, ranibizumab intravitreal injection
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans

NCT02154906
View directory record Official record
Conditions
Periodontitis
Interventions
DFDBA, autologous platelet rich fibrin
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 13, 2026, 2:49 AM EDT
Not listed Phase 2 Interventional

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

NCT00812513
View directory record Official record
Conditions
Burns, Electric Burns
Interventions
R-Pdf/Gbb 0.01% gel
Drug
Lead sponsor
American Scitech International
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Not applicable Interventional

Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy

NCT01674101
View directory record Official record
Conditions
Osteosarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Sarcoma, Malignant Fibrous Histiocytoma of the Bone, Chondrosarcoma of the Bone
Interventions
Endurance, Strengthening, Stretching, Home exercise program
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 13, 2026, 2:49 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Immediate Implant Placement Using Volume-Stable Collagen Matrix Combined With rhPDGF-BB

NCT06038695
View directory record Official record
Conditions
Tooth Extraction, Immediate Implant Placement
Interventions
Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB
Device
Lead sponsor
I-Ching Wang
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 13, 2026, 2:49 AM EDT
Not listed Phase 1 Interventional

PEP on a Skin Graft Donor Site Wound

NCT04664738
View directory record Official record
Conditions
Skin Graft
Interventions
10% PEP, TISSEEL, 20% PEP
Biological · Drug
Lead sponsor
Rion Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Doral, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 13, 2026, 2:49 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences

NCT05576922
View directory record Official record
Conditions
Implant Complication
Interventions
Prosthetic-surgical approach + autogenous graft, Prosthetic-surgical approach + graft substitute
Other
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Inovium Ovarian Rejuvenation Trials

NCT03178695
View directory record Official record
Conditions
Perimenopausal Disorder, Menopause, Menopause, Premature, Menopause Related Conditions, Menopause Premature Symptomatic, Menopause Premature Asymptomatic, Premature Ovarian Failure, Premature Ovarian Failure, Familial, Premature Ovarian Failure 2A, Premature Ovarian Failure 3, Premature Ovarian Failure 4, Premature Ovarian Failure 1, Premature Ovarian Failure 5, Premature Ovarian Failure 6, Premature Ovarian Failure 7, Premature Ovarian Failure 9, Premature Ovarian Failure 8, Infertility, Infertility, Female, Infertility Unexplained
Interventions
Autologous PRP injection into human ovarian tissue
Other
Lead sponsor
Ascendance Biomedical
Industry
Eligibility
35 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

NCT00003597
View directory record Official record
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 13, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

NCT04631211
View directory record Official record
Conditions
Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders, Myelodysplastic Syndromes, Platelet Refractoriness
Interventions
Thrombosomes, Liquid Stored Platelets (LSP)
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Duarte, California • Washington D.C., District of Columbia • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 2 Interventional

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT05714969
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Gainesville, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 13, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

NCT00367991
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Recombinant human erythropoietin alfa (drug), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 13, 2026, 2:49 AM EDT